The Center for Technology Licensing (CTL) is Cornell University's technology transfer office.
We manage technology for Cornell's Ithaca campus, Weill Cornell Medical Colleges, Cornell Tech, and Cornell AgriTech in Geneva.
The Center for Technology Licensing’s mission is to bring the University's scientific discoveries, technological innovations, and medical advances
to the marketplace for societal benefit and to foster economic development within New York State and across the nation. Below is a selection of
technologies developed at Cornell and managed by CTL. For more information about these and other innovations available for licensing, please e-mail
After Margaret Bynoe and her lab discovered that an FDA-approved drug, Lexiscan, used in cardiac imaging, could open the blood-brain barrier, the lab went to work, exploring how it could be used as a therapeutic for brain diseases.
Ilana L. Brito and her team are developing a suite of computational tools for examining the mobile gene content in multiple datasets — to identify those genes that may shape the response of microbial communities to stress.
Samie Jaffrey’s team created a synthetic RNA strand designed to bind to a fluorescent dye. Named ‘Spinach’ for its green fluorescence, this tag suddenly made it possible to image RNA as it went through its life cycle in living cells.
Tracking the migration of birds—especially smaller species like songbirds—will now be much easier with the development of new lightweight, solar-powered tags that can even outlast the lifespans of most birds.
David Putnam and Lawrence Bonassar investigate synthetic mimetics of the natural proteoglycan lubricant, lubricin, to delay or prevent progression of osteoarthritis (OA) following injury to the weight-bearing articular cartilage of the knee.
Dr. Hening Lin is an Investigator in the Howard Hughes Medical Center and Professor of Chemistry and Chemical Biology at Cornell University. Dr. Lin’s understanding of sirtuin enzymatic activity has enabled the development of a potent sirtuin2-specific inhibitor called “TM.”
Dr. Benedict Law is an Assistant Professor of Pharmacology in Radiology at Weill Cornell Medicine. Dr. Law’s team is interested in a new type of two-dimensional nanomaterial, such as nanofiber (PF) that is biocompatible, able to penetrate inside a tumor, and has a short circulation time to avoid non-specific in vivo distribution with a high tumor uptake.
Dr. Robert Shepherd, Assistant Professor of Mechanical and Aerospace Engineering, and his team have developed foam actuators and sensors to create soft robotics that are safe for use in prosthetics and enhance augmented and virtual reality experiences.
Paul Steen, Professor in Chemical and Biomolecular Engineering, has developed a switchable electronically- controlled adhesion device that allows for maximum adhesion to various surfaces. Among the applications for the device are wafer handling, large-format printing, gripping gloves and shoes, and drone parking pods.